Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets is expected to increase in value at a CAGR of 7.1% by 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

ResearchMoz added Latest Research Report titled " Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth " to it's Large Report database.

Diabetes Mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 90-95% of all diabetics have T2DM.

T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control, as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=811828

Scope

The current South-East Asia T2DM market contains novel products, including Jardiance, a SGLT-2 inhibitor; Victoza, a GLP-1 receptor agonist; and Januvia, a DPP-4 inhibitor.

What are the competitive advantages of the existing novel drugs?
With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, featuring improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.
Which classes of novel drugs are most prominent within the pipeline?
Is there strong potential for the pipeline to address unmet needs within the T2DM market?
Analysis of clinical trials since 2006 identified that the failure rates of T2DM molecules were highest in Phase III, at 49%, with the overall attrition rate for T2DM standing at 75%.
How do failure rates vary by product stage of development, molecule type, and mechanism of action?
How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?

Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 10
2.3 Symptoms 11
2.4 Etiology and Pathophysiology 11
2.5 Diagnosis 14
2.6 Classification 15
2.7 Prognosis 15
2.8 Treatment Options 16
2.8.1 Treatment Algorithm 16
2.8.2 Non-insulin T2DM Therapies 18
2.8.3 Insulin T2DM Therapies 21
2.9 Treatment Segments 22
2.9.1 Non-insulin therapies 23
2.9.2 Insulin Therapies 38
2.10 Co-morbidities and Complications 41

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

This release was published on openPR.